Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Carbamazepine on S-892216 PK in Healthy Adults
NCT06751017Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of S-892216 in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd. Primary endpoints: Plasma Concentration of S-892216 at Day 35, Time to Maximum Plasma Concentration (Tmax) of S-892216 at Day 35 and 2 more. Started Dec 2024; status: completed.
02
Drugs
S-892216
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06751017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751017.